Background. Laparoscopic thermal ablation is a common alternative to surgical resection in treating hepatic tumors, particularly in those located in difficult-to-reach locations. Objective. The aim of this study was to compare the safety and long-term efficacy of laparoscopic radiofrequency ablation (RFA) and microwave ablation (MWA) in treating hepatocellular carcinoma (HCC). Method. From February 2009 to May 2015, data from patients with HCC nodules who had undergone either laparoscopic MWA or laparoscopic RFA were examined. Complications, complete ablation rates, local tumor progression (LTP) rates, and disease-free and cumulative survival rates were compared between the two treatment groups. Results. A total of 154 patients with HCC (60 MWA and 94 RFA) were treated via the laparoscopic approach. Major complication rates were identified as 1 and 2 % in the RFA and MWA groups, respectively (p = 0.747). Complete ablation rates were 95 % for both treatment groups (p = 0.931), and LTP rates were 21.2 % for RFA and 8.3 % for MWA (p = 0.034). Disease-free survival rates at 5 years were 19 % in the RFA group and 12 % in the MWA group (p = 0.434), while cumulative survival rates at 5 years were 50 % in the RFA group and 37 % in the MWA group (p = 0.185). Conclusion. Laparoscopic RFA and MWA appear to be safe in the treatment of early-stage HCC. The LTP rates were lower in the laparoscopic MWA group compared with the laparoscopic RFA group, but their respective overall and disease-free survival rates remained similar.
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Treatment options for hepatocellular carcinoma (HCC) currently include liver transplant, surgical resection, thermal ablation, transarterial chemoembolization (TACE), and targeted agents such as sorafenib. 1 Among these options, ultrasound (US)-guided radiofrequency ablation (RFA) is the most widely utilized technique for treating small HCCs \3 cm in diameter. [2] [3] [4] Due to its percutanous approach, RFA can treat small tumors with less blood loss and fewer complications compared with surgical resection. [5] [6] [7] [8] [9] One limitation of RFA is its inability to heat tumors larger than 3 cm in size or around nearby blood vessels that may act as a heat sink. [10] [11] [12] Incomplete ablations in these circumstances may lead to high rates of local tumor progression (LTP). Physicians have begun addressing these deficiencies by using high-powered microwave ablation (MWA) systems, which utilize an electric field to heat tissue. This penetrating electric field can create larger ablation zones and heat tumor tissue to hotter temperatures than compared with RFA. 13, 14 Despite the benefits associated with percutaneous ablation, there are sitill HCC cases that are not amenable to a direct percutaneous approach due to the location of the nodule, particularly if it is near the capsule or diaphragm. [15] [16] [17] [18] An alternative method of treating these nodules is to utilize a laparoscopic approach, 19 which allows the physician to grossly examine the tumor spread, improve tumor staging via intra-operative US (IOUS) and identify safer insertion paths to treat tumors located in difficult locations. [20] [21] [22] [23] Laparoscopic treatment strategies with MWA or RFA have only recently been adopted to reduce complication rates. 16, 19 Long-term clinical results from laparoscopic MWA treatment of HCC have not yet been characterized in the literature. The purpose of this retrospective comparative study between laparoscopic MWA and RFA for HCC was to compare their respective technical success, complication rates, and rates of LTP, as well as survival rates.
MATERIALS AND METHODS
Institutional Review Board approval and written consent from all patients were obtained prior to the beginning of this retrospective study. All patients with HCC were treated with either laparoscopic MWA or RFA, as determined by our multidisciplinary tumor board, from February 2009 to May 2015. The Barcelona clinic liver cancer (BCLC) criteria were utilized as a broad framework for deciding appropriate treatment strategies. 3 Inclusion criteria for ablation therapies were a single lesion with a diameter \5 cm or two to three lesions \3 cm in diameter, unresectable due to the risk of complications; Child-Pugh class A cirrhosis (selected patients with Child-Pugh class B cirrhosis); early recurrence after surgical resection; or percutaneous RFA or the patient's desire to decline surgery. 16, 19 RFA was the dominant ablation modality at the initiation of the study period, but MWA became the preferred ablation modality in the later stages of the study as MWA safety data became known.
Laparoscopic ablation therapies were offered to patients meeting at least one of the following criteria including severe impairment of coagulation tests [platelets \40,000 and/or international normalized ratio (INR) [1.2] ; superficial lesions adjacent to abdominal viscera that could easily be displaced during the laparoscopic maneuvers; deeply-seeded lesions that were not amenable to percutaneous approaches (i.e. not visible at US, or proximal to primary biliary or portal tributaries). The exclusion criteria were complete portal vein thrombosis or pre-existing severe liver disease (class C according to the Child-Pugh classification). 16, 19 Procedure All patients underwent intraoperative US examination (Aloka Alfa 10; Aloka Co., Tokyo, Japan) by surgeons trained in US techniques and ablations. 16, 19 The laparoscopic US (LUS) probe had a flexible tip and dimensions of 10 mm in diameter and 50 cm in length. 24 
Pre-and Post-Treatment Evaluation
Preoperative assessment included an US study of the liver and a triple-phase spiral contrast-enhanced computed tomography (CT) scan to confirm the HCC diagnosis and location. In selected cases where CT or US imaging was equivocal, magnetic resonance imaging (MRI) of the liver was utilized.
Postoperative mortality was defined as occurrence of death within 90 days after treatment. We used the common toxicity criteria of the National Cancer Institute and the Clavien-Dindo classification of surgical complications to index pain and postoperative morbidity, respectively.
27,28
US and CT scans were performed at 1 and 3 months to evaluate treatment response and complications. Afterwards, the post-treatment response was evaluated with CT every 6 months. A single, experienced radiologist with 10 years of expertise in ablation techniques and images reviewed all CT/MRI examinations.
Technical outcome and oncologic response were defined using the International Working Group on image-guided tumor ablation 29 standardized definitions. Technical success was defined by the tumor lesion being completely covered by the ablation zones at the 1-month follow-up examinations with contrast-enhanced imaging. LTP was defined by the reappearance of tumor foci within the edge of the ablation zone. We defined intrahepatic recurrence to include LTP, but also extending to the boundaries of the entire liver and not limited to the original ablation zone. 29 Patients who did not show a complete local response after the first ablation session immediately underwent either additional ablation sessions or TACE. Patients with LTP or intrahepatic recurrence were treated with appropriate therapies following the European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases (AASLD) guidelines. 3, 4 Statistical Analysis Kaplan-Meier curves, which included overall survival, disease-free survival, intrahepatic recurrences, and LTP curves, were created and compared using the log-rank test. Characterization of baseline patient characteristics between the RFA and MWA groups were carried out using the Mann-Whitney U test and Wilcoxon matched pairs test. Data distributed in a normal distribution were expressed as mean ± SD; if data were non-parametric, median and IQR values were reported. Comparisons of proportions were undertaken using the two-sided Pearson's Chi-square test or Fisher's exact test, depending on sample size. The association of each parameter with survival and recurrence rates was estimated via univariate analysis. Significant parameters with p values \ 0.05 were then included in a multivariate analysis. For each parameter analyzed in the multivariate analyses, p values, hazard ratio, and 95 % confidence intervals (CI) were obtained. All analyses were performed using commercial statistical software (Statistica-Mac; Statsoft, Tulsa OK, USA).
RESULTS
A total of 458 consecutive patients were identified to have undergone laparoscopic ablation for HCC at our institution (Fig. 1) . Among this cohort, 215 patients were excluded because they were treated before February 2009, the year MWA procedures began at our institution. Additional patients were excluded due to Child-Pugh class B liver function (n = 24), BCLC B/C stage (n = 17), surgical resection in association with an ablation therapy (n = 8), or nodule diameter [3 cm (n = 40). After the exclusion process, 154 patients were available for analysis (MWA 60 and RFA 94).
The baseline characteristics of patients allocated to MWA or RFA are described in Table 1 and electronic  supplementary Table 1 . A significant difference in the maximum diameter of HCC nodules was observed between MWA and RFA (21.
was observed in 6 % (6/94) of patients after RFA and 18 % (11/60) of patients after MWA (p = 0.021). Pain was relieved with a short course of non-steroidal anti-inflammatory medication. After RFA and MWA, six patients (6 %) and five patients (8 %), respectively, had a low-grade fever lasting 12-72 h after the procedure, all of which self-resolved (p = 0.647). The overall morbidity rate was 19 % after RFA and 23 % after MWA (p = 0.747) ( Table 2 ). In one patient, after MWA, a pleural effusion required a pleuric drainage (Clavien-Dindo class 3A), while in another patient, after RFA, a wall hematoma at the trocar access formed, requiring a surgical hemostasis (Clavien-Dindo class 3B).
The mean follow-up period of patients was 31 ± 19.5 months (median 26.9; range 15-45.8 months). Technical success was achieved in 95 % (89/94) of patients treated with RFA and 95 % (57/60) of patients treated with MWA (p = 0.931). A significantly higher rate of LTP incidence was observed in RFA patients compared with MWA patients (20 cases 21.3 % vs. five cases 8.3 %; p = 0.034), as well as their respective Kaplan-Meier curves (p = 0.047) [Fig. 2a] . Sixteen patients had LTP that could be re-treated (three MWA, five RFA, and eight TACE), while two patients refused the new treatment, one patient had liver insufficiency, and one patient showed multiple lesions (15 patients obtained a complete ablation after the re-treatment, while one patient submitted to TACE showed an incomplete necrosis). All five patients with LTP after MWA were succesfully re-treated (one MWA, two RFA, and two TACE). In the RFA group, an LTP rate of 21. The cumulative intrahepatic tumor recurrence rates in the MWA group at 1, 3 and 5 years were 39 %, 69 % and 80 %, respectively, whereas in the RFA group, these rates were 33 %, 68 % and 77 %, respectively (p = 0.679) [Fig. 2b ]. The two groups demonstrated similar rates of overall survival (p = 0.185) [ Fig. 2c ] and cumulative disease-free survival (p = 0.434) [Fig. 2d ]. The causes of death included HCC progression in 17 patients (28 %), hepatic failure in 7 patients (12 %), and other extrahepatic causes in 4 patients (7 %) in the MWA group, while in the RFA group, causes of death included HCC progression in 18 patients (19 %), hepatic failure in 9 patients (10 %), and other extrahepatic causes in 10 patients (11 %) (p = 0.400).
DISCUSSION
Laparoscopic approaches for thermal ablation provide access to difficult tumors, particularly if the tumors are located underneath the liver capsule, adjacent gallbladder, or diaphragm. 18, 19 In this study, we compared the efficacy, complication rates, and long-term outcomes between laparoscopic MWA and RFA procedures. Our results demonstrate that both laparoscopic approaches are associated with near-complete technical success and low complication rates, similar to previously reported percutaneous RFA results in treating HCC nodules. 30, 31 No significant differences were found between ablation groups in terms of recurrence rates, and disease-free and overall survival rates. However, our study revealed a lower incidence of LTP in the MWA group compared with the RFA group (8 % vs. 21 %; p = 0.034).
With regard to the safety of both laparoscopic MWA or RFA, the present study found no perioperative mortality and a low incidence of postoperative complications: 19 % after RFA and 23 % after MWA, with major complication (Clavien-Dindo classes 3A and 3B) rates \2 %. These values are comparable to the safety profiles found in previous clinical ablation studies. 2, 31 A recent systematic review comparing both ablation modalities (radiofrequency and microwave) also reported similar data for both techniques, with low rates of complications; major complication rates associated with RFA and MWA were 4.1 and 4.6 %, respectively. 32 In our study, only two cases (1.3 %) required an invasive procedure (pleural drainage and surgical wound hemostasis) and eight cases (5.2 %) required further pharmacological treatment or blood transfusions.
Current literature concerning complete ablation and LTP rates of MWA versus RFA are controversial. 33, 34 In our study, a lower incidence of LTP was observed in the MWA group compared with the RFA group. MWA systems create larger margins and overcome the heat-sink effect, shutting off vessels that can be related to LTP. 35, 36 In our experience, LTP rates increase from 18 to 45 % if the lesion is near a major vessel after RFA, while no LTP was registered for these lesions after MWA. Direct clinical trial results comparing LTP rates among patients undergoing MWA and RFA are equivocal, with many studies treating larger tumors with MWA and smaller tumors with RFA. 37, 38 Since the size of the nodule is a well-known factor associated with LTP, there are questions about the generalizability of these previous results. 30, 39 Survival outcomes after RFA for HCC can be improved by minimizing the risk for LTP. We found that LTP was significantly higher in the RFA group than in the MWA group, but had similar overall survival rates. Survival rates may have been related to our protocol of immediate treatment after LTP detection with repeat RFA, MWA, or TACE; only four patients had no followup treatment and another patient showed an incomplete necrosis after TACE. A retrospective study of 171 patients who underwent RFA for HCC who met the Milan criteria had similar conclusions; cumulative survival rates were significantly higher in patients without LTP than in those with LTP (p \ 0.001). 40 There were limitations to our study design. The retrospective, unblinded nature of our analysis may have introduced bias to the results, especially since RFA procedures were performed earlier in the study, while MWA procedures were performed predominantly in the later points of the study. At our institute, we prefer to use MWA if the HCC nodule diameter is [20 mm. This decision to treat tumors between 2 and 3 cm in size with MWA, and smaller HCC nodules with RFA, presents a potential bias in the reported results that could influence overall survival. However, overall HCC recurrences were not statistically different and, above all, LTP rates of the RFA patients were higher than that of the MWA patients, despite their smaller nodules. As previously described, repeated treatments received by patients at HCC recurrence could represent a potential confounder for interpreting survival data.
CONCLUSIONS
Our study showed that laparoscopic ablations with both RFA or MWA can be a safe and effective alternative in patients with HCC located in difficult-to-reach locations. There were no mortalities in either group and no difference in the rates of postoperative complications. The LTP rates in patients treated with MWA were lower than those treated with RFA; however, this finding had little impact on overall survival and intrahepatic recurrence rates, which were similar between each group. A multicenter, prospective, randomized controlled trial is warranted to confirm these results.
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